Compare Ascendis Pharma A/S (ASND) vs Extra Space Storage, Inc. (EXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Extra Space Storage, Inc. — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Extra Space Storage, Inc. trades at $145.13 (market cap $30.41B). The key difference: Extra Space Storage, Inc. is the larger of the two by market cap, and Extra Space Storage, Inc. pays a 4.5% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | EXR | |
|---|---|---|
Market Cap | $17.74B | $30.41B |
Sector | Health | Real Estate |
52-Week High | $277.18 | $152.75 |
52-Week Low | $163.32 | $126.67 |
Enterprise Value | $18.11B | $44.21B |
Dividend Yield | — | 4.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Extra Space Storage (EXR) trades at $143.96, up 0.9% on the day, with a bearish technical signal from moving averages despite recent earnings beats. The company reported strong fundamentals with 2025 revenue of $3.38B and net income of $974M, though profitability margins have moderated from prior peaks. Recent news includes a $550M senior notes offering and the release of its 2025 sustainability report, indicating ongoing capital management and operational focus.
Outlook is mixed: analyst consensus is a Buy with a $155.88 price target, but technical weakness and expense growth pose near-term risks. The stock offers income via a $1.62 dividend, yet investors face headwinds from competitive pressures and potential occupancy declines. Valuation remains elevated with a P/E of 32.35, requiring sustained earnings growth to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →
